TAVNEOS 10 mg, hard capsule 180 capsules
Active ingredients: Avacopan
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule180 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAVNEOS 10 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 180 gélule(s)
- Marketing authorisation holder
- VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 4 Aug 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69292539CIP73024694CIP133400930246948Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| AVACOPANgélule | 10 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.